OKYO Pharma Ltd - Form 20-F Summary (Fiscal Year Ended March 31, 2025)
Business Context and Reporting Period
Company: OKYO Pharma Ltd (Guernsey-incorporated, NASDAQ: OKYO)
Reporting Period: Fiscal year ended March 31, 2025
Business Model: Clinical-stage biopharmaceutical company developing therapeutics for inflammatory eye diseases and ocular pain. The company has no product revenue and relies on equity and debt financing.
Key Assets: Lead candidate urcosimod (formerly OK-101) for Neuropathic Corneal Pain (NCP) and Dry Eye Disease (DED); secondary candidate OK-201.
Key Financial Metrics
| Metric (in thousands, except per share) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(4,706) | $(16,825) | $(13,272) |
| Loss Per Share (Basic/Diluted) | $(0.20) | $(0.57) | $(0.61) |
| Cash and Cash Equivalents (End of Period) | $1,561 | $827 | $4,045 |
| Working Capital | $(5,552) | $(5,883) | $(2,060) |
| Total Assets | $3,677 | $1,541 | $5,204 |
| Total Liabilities | $9,227 | $7,421 | N/A |
| Shareholders' Equity (Deficit) | $(5,550) | $(5,880) | $(2,053) |
Material Changes vs. Prior Period
- Significant Reduction in Net Loss: Net loss decreased by approximately $12.1 million (72%) compared to 2024. This was primarily driven by a $3.26 million income tax credit (R&D tax rebates) and a reduction in operating expenses.
- Operating Expenses: Total operating expenses dropped from $15.75 million in 2024 to $7.09 million in 2025.
- R&D Expenses: Decreased from $8.24 million to $2.25 million due to the completion of the large-scale DED Phase 2b trial and the initiation of a smaller, less costly NCP Phase 2 trial.
- G&A Expenses: Decreased from $7.51 million to $4.84 million due to reduced bonuses, lower D&O insurance premiums, and decreased option charges.
- Liquidity Position: Cash balances increased to $1.56 million from $0.83 million, supported by $1.7 million in equity fundraising and $0.95 million in convertible loan note proceeds during the year.
- Going Concern: The independent auditor (PKF Littlejohn LLP) has expressed substantial doubt about the company's ability to continue as a going concern, citing liquidity constraints post-July 2026 without additional financing.
Guidance, Outlook, and Risks
- Clinical Progress:
- Urcosimod (NCP): The company announced results from an 18-patient Phase 2 trial in July 2025. The 0.05% dose showed a strong treatment effect (Cohen-d > 1.2) and statistically significant pain reduction (p=0.025) compared to placebo, though the between-group difference did not reach statistical significance (p=0.07) due to the small sample size. The trial was closed early to analyze data.
- Regulatory Status: Received FDA Fast Track designation for urcosimod for NCP in May 2025.
- Capital Needs: Management states existing cash is insufficient to fund operations beyond the near term. The company expects to raise additional capital through equity offerings or debt arrangements to continue clinical trials and operations.
- Key Risks:
- Liquidity: Substantial doubt regarding ability to continue as a going concern without further funding.
- Development Risk: High failure rate in clinical trials; urcosimod is still in early clinical stages.
- Third-Party Dependence: Reliance on CROs and CMOs for trials and manufacturing.
- Intellectual Property: Reliance on licensed patents from Tufts Medical Center and On Target Therapeutics.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline of cash burn and the status of the post-balance sheet $2.7 million ATM facility raise mentioned in the filing.
- Going Concern Mitigation: Review the specific steps management is taking to secure funding before the July 2026 liquidity horizon identified by auditors.
- Clinical Trial Data: Scrutinize the full data set from the 18-patient NCP Phase 2 trial, particularly the statistical power and the rationale for early closure.
- Convertible Debt: Assess the dilution impact of the $950,000 in convertible loan notes issued in 2025 (convertible at $0.70/share) and related party loans.
- R&D Tax Credits: Confirm the sustainability of the $3.26 million tax credit, which significantly reduced the reported net loss, and the likelihood of future rebates.